ResMed (MEX:RMD) Cyclically Adjusted Revenue per Share: MXN509.13 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RMD ResMed Inc MEX:RMD
97 GF Score
Price MXN3,841.00
GF Value MXN4,672.86
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Cyclically Adjusted Revenue per Share?

ResMed MEX:RMD 97 Cyclically Adjusted Revenue per Share is MXN509.13 as of Jun. 2026. GuruFocus rates MEX:RMD with a GF Score™ of 97/100 and a GF Value™ of MXN4,672.86 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ResMed's adjusted revenue per share for the three months ended in Jun. 2026 was MXN176.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN509.13 for the trailing ten years ended in Jun. 2026.

During the past 12 months, ResMed's average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ResMed was 26.90% per year. The lowest was 11.20% per year. And the median was 14.15% per year.

As of today (2026-08-16), ResMed's current stock price is MXN3841.00. ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN509.13. ResMed's Cyclically Adjusted PS Ratio of today is 7.54.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ResMed was 18.37. The lowest was 6.15. And the median was 9.72.


ResMed  (MEX:RMD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ResMed's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3841.00/509.13
=7.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ResMed was 18.37. The lowest was 6.15. And the median was 9.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ResMed Cyclically Adjusted Revenue per Share Related Terms


ResMed Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ResMed's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Cyclically Adjusted Revenue per Share Chart

ResMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 374.59 385.96 477.16 477.31 509.13

ResMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 477.31 499.04 502.49 506.26 509.13

MEX:RMD vs MDLN, WST, COO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted PS Ratio falls into.


MEX:RMD
97GF Score
ResMed Inc MEX:RMD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=176/333.9520*333.9520
=176.000

Current CPI (Jun. 2026) = 333.9520.

ResMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 63.338 241.428 87.611
201612 76.956 241.432 106.447
201703 67.837 243.801 92.921
201706 70.505 244.955 96.121
201709 66.235 246.819 89.618
201712 82.088 246.524 111.200
201803 74.651 249.554 99.898
201806 84.942 251.989 112.571
201809 76.399 252.439 101.068
201812 88.566 251.233 117.727
201903 89.002 254.202 116.924
201906 93.452 256.143 121.840
201909 92.664 256.759 120.523
201912 95.373 256.974 123.943
202003 123.848 258.115 160.236
202006 121.674 257.797 157.617
202009 113.697 260.280 145.879
202012 108.685 260.474 139.344
202103 107.993 264.877 136.156
202106 118.943 271.696 146.197
202109 126.572 274.310 154.092
202112 124.847 278.802 149.543
202203 117.126 287.504 136.048
202206 125.129 296.311 141.024
202209 129.917 296.808 146.175
202212 136.724 296.797 153.840
202303 136.586 301.836 151.119
202306 130.310 305.109 142.629
202309 130.190 307.789 141.257
202312 133.774 306.746 145.639
202403 134.726 312.332 144.052
202406 151.871 314.175 161.431
202409 163.354 315.301 173.017
202412 181.304 315.605 191.844
202503 179.504 319.799 187.448
202506 172.589 322.561 178.684
202509 166.783 324.800 171.483
202512 175.024 324.054 180.370
202603 177.131 330.213 179.137
202606 176.000 333.952 176.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN509.13 mean?
ResMed (MEX:RMD) has a Cyclically Adjusted Revenue per Share of MXN509.13 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ResMed and its competitors.
Is ResMed's Cyclically Adjusted Revenue per Share too high?
ResMed's current Cyclically Adjusted Revenue per Share is MXN509.13. Overall, ResMed has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Cyclically Adjusted Revenue per Share compare to MDLN and WST?
ResMed's Cyclically Adjusted Revenue per Share of MXN509.13 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ResMed and its competitors. ResMed's current Cyclically Adjusted Revenue per Share is MXN509.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN4,672.86, compared to a current price of MXN3,841.00 — trading 17.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN509.13. ResMed's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Cyclically Adjusted Revenue per Share is MXN509.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (MEX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of MXN3,841.00 is trading 17.8% below its estimated GF Value™ of MXN4,672.86. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for MEX:RMD:

  • Cyclically Adjusted Revenue per Share: MXN509.13
  • GF Value™: MXN4,672.86 vs. price of MXN3,841.00 (17.8% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
97GF Score

Get the complete analysis for MEX:RMD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,841.00
Price
MXN4,672.86
GF Value